Arcturus Therapeutics (NASDAQ:ARCT) Upgraded to "Strong-Buy" at Zacks Research

Key Points

• Arcturus Therapeutics has been upgraded to a "Strong-Buy" rating by Zacks Research, indicating positive sentiment from analysts towards the company.
• The stock of Arcturus Therapeutics increased by 9.6%, reaching an opening price of $21.25, while the stock has experienced a 12 month range between $8.04 and $23.59.
• The company's latest earnings report showed an earnings per share (EPS) of ($0.34), surpassing analysts' expectations and generating revenue of $28.30 million for the quarter.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) was upgraded by stock analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a note issued to investors on Monday,Zacks.com reports.

A number of other equities analysts have also commented on ARCT. Wall Street Zen upgraded shares of Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Arcturus Therapeutics in a research report on Wednesday, October 8th. HC Wainwright initiated coverage on shares of Arcturus Therapeutics in a research note on Thursday, September 4th. They issued a "buy" rating and a $60.00 target price for the company. Citigroup reaffirmed a "buy" rating on shares of Arcturus Therapeutics in a research note on Friday. Finally, Leerink Partners dropped their target price on shares of Arcturus Therapeutics from $63.00 to $54.00 and set an "outperform" rating for the company in a research note on Friday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $50.57.

Arcturus Therapeutics Stock Up 9.6%

NASDAQ:ARCT opened at $21.25 on Monday. The firm has a market cap of $577.04 million, a PE ratio of -9.53 and a beta of 2.39. Arcturus Therapeutics has a 12 month low of $8.04 and a 12 month high of $23.59. The company's 50-day moving average price is $18.25 and its two-hundred day moving average price is $14.33.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($1.11) by $0.77. The firm had revenue of $28.30 million for the quarter, compared to analyst estimates of $17.64 million. Arcturus Therapeutics had a negative net margin of 49.26% and a negative return on equity of 24.87%. On average, research analysts expect that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Arcturus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd bought a new stake in shares of Arcturus Therapeutics during the first quarter worth approximately $299,000. Goldman Sachs Group Inc. raised its stake in shares of Arcturus Therapeutics by 9.1% during the first quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company's stock worth $5,398,000 after buying an additional 42,636 shares during the last quarter. Invesco Ltd. raised its stake in shares of Arcturus Therapeutics by 83.1% during the first quarter. Invesco Ltd. now owns 34,896 shares of the biotechnology company's stock worth $370,000 after buying an additional 15,836 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its stake in shares of Arcturus Therapeutics by 20.6% during the first quarter. Jacobs Levy Equity Management Inc. now owns 144,141 shares of the biotechnology company's stock worth $1,526,000 after buying an additional 24,583 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new stake in Arcturus Therapeutics in the first quarter valued at approximately $244,000. 94.54% of the stock is owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.